Cargando…
Case Series of Steroid-Resistant Immune Checkpoint Inhibitor Associated Myocarditis: A Comparative Analysis of Corticosteroid and Tofacitinib Treatment
Background: Immune checkpoint inhibitor (ICI)–associated myocarditis is an uncommon and potentially fatal immune-related adverse event (irAE). Although corticosteroids are recommended as the first-line treatment by current guidelines, patients still have variable responses to it, and the guidelines...
Autores principales: | Wang, Cong, Lin, Jinyi, Wang, Yan, Hsi, David H., Chen, Jiahui, Liu, Tianshu, Zhou, Yuhong, Ren, Zhenggang, Zeng, Zhaochong, Cheng, Leilei, Ge, Junbo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8685452/ https://www.ncbi.nlm.nih.gov/pubmed/34938185 http://dx.doi.org/10.3389/fphar.2021.770631 |
Ejemplares similares
-
Case Report: Treatment for steroid-refractory immune-related myocarditis with tofacitinib
por: Xing, Qian, et al.
Publicado: (2022) -
Treatment of corticosteroid refractory immune checkpoint inhibitor myocarditis with Infliximab: a case series
por: Zhang, Robert S., et al.
Publicado: (2021) -
Immune Checkpoint Inhibitor-Related Myositis Overlapping With Myocarditis: An Institutional Case Series and a Systematic Review of Literature
por: Nakagomi, Yuki, et al.
Publicado: (2022) -
Drug therapy for myocarditis induced by immune checkpoint inhibitors
por: Wu, Yihao, et al.
Publicado: (2023) -
A model-informed approach to assess the risk of immune checkpoint inhibitor-induced autoimmune myocarditis
por: van der Vegt, Solveig A., et al.
Publicado: (2022)